RxDoctor Payments DataLook up a doctor →

Keifong Seeto, MD

Neurology · Salem, ORNPI 1962447730

Payments from drug & device makers

$18,017in general payments, 2019–2025

Across 1,003 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$2K
  • Sunovion Pharmaceuticals Inc.$1K
  • SK Life Science, Inc.$1K
  • Bristol Myers Squibb$944
  • EMD Serono, Inc.$820
  • plus $11K from 46 others

What the payments were for

  • Speaking & faculty fees$2742%
  • Food & beverage$17,60398%
  • Education$1391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,017 in reported general payments places this provider in the 80th percentile of 228 neurology providers in Oregon.

See all neurology providers in Oregon

Medicare billing

Part B allowed, 2024
$103,042
Medicare patients
222
Services billed
666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate95$118,811
AptiomEslicarbazepine Acetate48$84,874
QuliptaAtogepant48$60,442
EpidiolexCannabidiol (Cbd)21$39,062
Aimovig AutoinjectorErenumab-Aooe34$30,591
Nurtec OdtRimegepant Sulfate26$25,659
Levetiracetam528$17,309
RytaryCarbidopa/Levodopa14$16,922
Lacosamide84$15,780
Carbamazepine ErCarbamazepine110$12,849
Carbidopa-LevodopaCarbidopa/Levodopa355$10,232
Carbamazepine155$9,416
Pregabalin127$9,382
Carbidopa-Levodopa ErCarbidopa/Levodopa218$9,360
Entacapone36$8,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$1,042$118,81195 claims
Sunovion Pharmaceuticals Inc.Aptiom$1,126$84,87448 claims
AbbVieQulipta$1,814$60,44248 claims
PfizerNurtec Odt, Dilantin$575$29,69842 claims
Amneal Pharmaceuticals LLCRytary$468$16,92214 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$115$8,64112 claims
Corium, LLCAdlarity$146$5,60313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 228 neurology providers in Oregon.

Other neurology in Salem

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →